Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATRA
stocks logo

ATRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.05M
-93.75%
-0.460
-61.34%
42.75M
-56.45%
2.460
-29.71%
1.85M
-89.48%
-0.570
-400%
Estimates Revision
The market is revising Upward the revenue expectations for Atara Biotherapeutics, Inc. (ATRA) for FY2025, with the revenue forecasts being adjusted by 0.96% over the past three months. During the same period, the stock price has changed by 9.99%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.96%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+9.99%
In Past 3 Month
Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 17.50 USD with a low forecast of 17.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 17.50 USD with a low forecast of 17.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.200
sliders
Low
17.00
Averages
17.50
High
18.00
Current: 14.200
sliders
Low
17.00
Averages
17.50
High
18.00
Mizuho
Salim Syed
Outperform
maintain
$16 -> $18
2025-11-20
Reason
Mizuho
Salim Syed
Price Target
$16 -> $18
2025-11-20
maintain
Outperform
Reason
Mizuho analyst Salim Syed raised the firm's price target on Atara Biotherapeutics to $18 from $16 and keeps an Outperform rating on the shares. The firm said it raised its price target on decreased operating expense, adding that it is watching the January 10, 2026 PDUFFA date for tab-cel and any word on the company's strategic alternatives valuation.
Canaccord Genuity
John Newman
Strong Buy
Maintains
$17
2025-03-11
Reason
Canaccord Genuity
John Newman
Price Target
$17
2025-03-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
n/a
2025-01-28
Reason
HC Wainwright & Co.
Robert Burns
Price Target
n/a
2025-01-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
n/a
2025-01-22
Reason
HC Wainwright & Co.
Robert Burns
Price Target
n/a
2025-01-22
Reiterates
Hold
Reason
Canaccord Genuity
John Newman
Strong Buy
Maintains
$21 → $17
2025-01-17
Reason
Canaccord Genuity
John Newman
Price Target
$21 → $17
2025-01-17
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Atara Biotherapeutics to $17 from $21 and keeps a Buy rating on the shares. The firm noted Atara received a Complete Response Letter (CRL) for Ebvallo on inspection findings from a third-party manufacturer, which we think can be resolved, with a 6-month review on resubmission. The target was reduced due to delayed Ebvallo approval and the potential to halt CAR-T development 1Q25.
Rodman & Renshaw
Tony Butler
Strong Buy
Initiates
$25
2024-12-20
Reason
Rodman & Renshaw
Tony Butler
Price Target
$25
2024-12-20
Initiates
Strong Buy
Reason
Rodman & Renshaw analyst Tony Buter initiated coverage of Atara Biotherapeutics with a Buy rating and $25 price target. Atara is developing T-cell immunotherapies with a focus on the development of therapies for patients with cancer and autoimmune diseases, the analyst tells investors in a research note. The firm believes Atara is unique for a number of reasons among allogeneic cell therapy developers given its use of intact T-cell receptors, the incorporation of the 1XX chimeric antigen receptors, and the use of T-cells with memory stem cell phenotype.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Atara Biotherapeutics Inc (ATRA.O) is 13.79, compared to its 5-year average forward P/E of -0.31. For a more detailed relative valuation and DCF analysis to assess Atara Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.31
Current PE
13.79
Overvalued PE
5.48
Undervalued PE
-6.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.40
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.36
Undervalued EV/EBITDA
-9.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.88
Current PS
0.00
Overvalued PS
35.53
Undervalued PS
-7.78
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 192.53% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ATRA News & Events

Events Timeline

(ET)
2025-11-12
09:12:31
Atara Biotherapeutics cuts its workforce by 29%
select
2025-11-12
09:11:53
Atara Biotherapeutics announces Q3 earnings per share of 32 cents, falling short of the consensus estimate of 67 cents.
select
2025-11-03 (ET)
2025-11-03
09:03:02
Pierre Fabre Reveals Transfer of BLA for Tabelecleucel from Atara Biotherapeutics
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-07NASDAQ.COM
Pacira (PCRX) Exceeds Q3 Earnings Projections

  • Earnings Performance: Pacira (PCRX) reported quarterly earnings of $0.7 per share, exceeding the Zacks Consensus Estimate of $0.65, but down from $0.79 per share a year ago, marking a +7.69% earnings surprise.

  • Revenue Insights: The company generated revenues of $179.52 million, missing the consensus estimate by 1.6%, and has not surpassed revenue estimates in the last four quarters.

  • Stock Outlook: Pacira shares have increased by about 16% this year, slightly outperforming the S&P 500, but the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Medical - Biomedical and Genetics industry ranks in the top 41% of Zacks industries, suggesting that industry performance could significantly influence Pacira's stock performance moving forward.

[object Object]
Preview
9.0
11-03PRnewswire
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

  • Tabelecleucel BLA Submission: The Biologics License Application (BLA) for tabelecleucel is under FDA Priority Review, with a target action date of January 10, 2026, potentially marking it as the first approved therapy for EBV+ PTLD in the U.S.

  • Significance for Patients: Tabelecleucel offers hope for patients with EBV+ PTLD, a rare and deadly blood malignancy, especially for those who have limited treatment options and a very short lifespan following initial treatment failure.

  • Transfer of Responsibilities: Pierre Fabre Pharmaceuticals has taken over all clinical development, regulatory, commercial, and manufacturing activities for tabelecleucel, having transferred the BLA from Atara Biotherapeutics.

  • Innovative Therapy Details: Tabelecleucel is an allogeneic, off-the-shelf T-cell immunotherapy targeting EBV-infected cells, with data from over 430 patients included in the BLA, highlighting its potential effectiveness in treating relapsed or refractory cases.

[object Object]
Preview
2.0
09-29Benzinga
4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance

  • Biotech Stocks Surge: Four biotechnology stocks—Arrowhead Pharmaceuticals, Assembly Biosciences, Atara Biotherapeutics, and Corcept Therapeutics—have entered the top 10th percentile for momentum ranking, indicating strong price action and investor interest in the healthcare sector.

  • Momentum Ranking Explained: The momentum percentile measures a stock's relative strength and recent performance compared to peers, with significant increases suggesting robust technical behavior and potential for further upside as institutional investors seek top-ranking stocks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Atara Biotherapeutics Inc (ATRA) stock price today?

The current price of ATRA is 14.2 USD — it has increased 13.15 % in the last trading day.

arrow icon

What is Atara Biotherapeutics Inc (ATRA)'s business?

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

arrow icon

What is the price predicton of ATRA Stock?

Wall Street analysts forecast ATRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRA is 17.50 USD with a low forecast of 17.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Atara Biotherapeutics Inc (ATRA)'s revenue for the last quarter?

Atara Biotherapeutics Inc revenue for the last quarter amounts to 3.45M USD, decreased -91.41 % YoY.

arrow icon

What is Atara Biotherapeutics Inc (ATRA)'s earnings per share (EPS) for the last quarter?

Atara Biotherapeutics Inc. EPS for the last quarter amounts to -0.32 USD, decreased -89.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Atara Biotherapeutics Inc (ATRA)'s fundamentals?

The market is revising Upward the revenue expectations for Atara Biotherapeutics, Inc. (ATRA) for FY2025, with the revenue forecasts being adjusted by 0.96% over the past three months. During the same period, the stock price has changed by 9.99%.
arrow icon

How many employees does Atara Biotherapeutics Inc (ATRA). have?

Atara Biotherapeutics Inc (ATRA) has 153 emplpoyees as of December 05 2025.

arrow icon

What is Atara Biotherapeutics Inc (ATRA) market cap?

Today ATRA has the market capitalization of 102.39M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free